Cardiologs Holter Platform vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 60/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A, the Cardiologs Holter Platform, is an AI-powered solution focused on the rapid and accurate analysis of Holter ECG data to detect various arrhythmias. Tool B, EchoGo Amyloidosis, is an AI-powered screening tool that analyzes echocardiogram video clips specifically for the early detection of cardiac amyloidosis. While both are cloud-based cardiology AI tools, they target different cardiac conditions and utilize distinct diagnostic data types, making them adjacent rather than direct competitors.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
The Cardiologs Holter Platform by Philips is an AI-powered solution designed for fast and accurate Holter ECG analysis, detecting over 20 types of arrhythmias. Ultromics' EchoGo Amyloidosis is an AI-powered screening tool that analyzes echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
The Cardiologs Holter Platform analyzes Holter ECG data and offers vendor-neutral compatibility with multiple Holter devices. EchoGo Amyloidosis analyzes echocardiogram video clips, specifically a single apical four-chamber view, to identify suspected cardiac amyloidosis.
The Cardiologs Holter Platform uses a 'pay per ECG regardless the number of users' pricing model, requiring contact with sales for details. EchoGo Amyloidosis has specific pricing and reimbursement codes: for inpatient analysis, it is $1,000 (Medicare-covered via NTAP Code ICD-10 XXE2X19), and for outpatient analysis, it is $285 (covered by Medicare and select commercial insurers via HCPCS Code C9786, Clinical APC Code 574).
The Cardiologs Holter Platform offers integration with Electronic Medical Record (EMR) systems, specifically Philips IntelliBridge Enterprise. EchoGo Amyloidosis provides seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7.
The Cardiologs Holter Platform reduces Holter analysis time by approximately 42% and detects over 20 types of arrhythmias. EchoGo Amyloidosis demonstrates high diagnostic accuracy with 85% sensitivity and 93% specificity for identifying suspected cardiac amyloidosis, with consistent performance across CA subtypes.